Equities

Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)36.22
  • Today's Change0.40 / 1.12%
  • Shares traded208.17k
  • 1 Year change+32.14%
  • Beta0.8953
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments255461340
Total Receivables, Net144165149
Total Inventory779286
Prepaid expenses171627
Other current assets, total------
Total current assets493734602
Property, plant & equipment, net434452
Goodwill, net117117118
Intangibles, net600702785
Long term investments1794119
Note receivable - long term------
Other long term assets8.511114
Total assets1,2781,7031,689
LIABILITIES
Accounts payable1.96119.33
Accrued expenses232237241
Notes payable/short-term debt04020
Current portion long-term debt/capital leases----0
Other current liabilities, total563865
Total current liabilities290688315
Total long term debt00379
Total debt0402379
Deferred income tax255085
Minority interest------
Other liabilities, total417993
Total liabilities356816873
SHAREHOLDERS EQUITY
Common stock0.060.050.05
Additional paid-in capital439408434
Retained earnings (accumulated deficit)483481380
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.59)(3.21)1.54
Total equity922886816
Total liabilities & shareholders' equity1,2781,7031,689
Total common shares outstanding555453
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.